Moderna is the most shorted S&P 500 stock, with 17.8% short float. But its cancer pipeline, flu approval, and international ...

Investors may be asking whether Moderna's current share price reflects its underlying worth, or if the market is mispricing ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its list of top short ideas for the second half of 2025. The ...

The FDA refused last week to consider Moderna's application to sell a flu vaccine in 2026-2027. Today, the FDA changed its mind. The FDA had previously rejected Moderna's application, refusing even to ...

Broader biotech positioning aligns with movements tracked across the nasdaq ecosystem.

Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...